Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2012 - 2026)

Enanta Pharmaceuticals has reported Accumulated Expenses for 15 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 77.64% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 77.64% YoY), and the FY2025 full-year result was $12.8 million, down 5.88% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.9 million, up from $2.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $36.7 million in Q2 2023, with the low at $2.4 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $13.7 million across 5 years, with a median of $6.9 million in 2026.
• The largest YoY upside for Accumulated Expenses was 934.07% in 2025 against a maximum downside of 85.22% in 2025.
• Enanta Pharmaceuticals' Accumulated Expenses stood at $15.2 million in 2022, then sank by 71.58% to $4.3 million in 2023, then fell by 5.03% to $4.1 million in 2024, then slumped by 41.34% to $2.4 million in 2025, then surged by 185.67% to $6.9 million in 2026.
• The last three Accumulated Expenses figures came in at $6.9 million (Q1 2026), $2.4 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.